NEW YORK, March 17, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Apollo Education Group, Inc. (“Apollo Education” or the “Company”) (Nasdaq:APOL) in the United States District Court for the District of Arizona on behalf of a class consisting of all persons or entities who purchased Apollo Education securities between June 26, 2013 and October 21, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants failed to disclose that a significant amount of revenue was generated through improper and aggressive recruiting tactics at U.S. military bases in violation of the Executive Order President Barack Obama signed on April 27, 2012.
The Complaint alleges that as a result of Defendants’ false statements during the Class Period, which emphasized Apollo’s financial success and bright financial prospects, the price of Apollo’s common stock allegedly traded at artificially inflated levels, reaching a Class Period high of $35.92 per share in intraday trading on January 22, 2014. With the price of the stock artificially inflated, the Complaint alleges that certain of Apollo’s senior executives sold their personal stock into the market at the artificially inflated prices, reaping almost $42 million in total proceeds.
On February 5, 2016, Apollo disclosed that it had received a second subpoena from the California attorney general's office, demanding documents "relating to marketing, recruiting, compensation of enrollment advisors, complaints, financial aid, compliance, accreditation, other governmental investigations, private litigation and other matters, as well as additional information relating to marketing and services to members and former members of the U.S. military and California National Guard" going back to July 1, 2010. In July 2015, the U.S. Federal Trade Commission also required the Company to produce documents concerning its business practices.
Apollo's stock has fallen in the twelve months from over $28 per share to today’s closing price of $8.28.
If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 



